Xavant Technology

The Future of Objective NMT Monitoring.

The Future of Objective NMT Monitoring.
Von der Theorie zur Praxis in der Neuromuskulären Blockade Überwachung

Von der Theorie zur Praxis in der Neuromuskulären Blockade Überwachung
Unlocking Anesthesiology's Future: Exclusive Interview with Dr. Wade Weigel

Unlocking Anesthesiology's Future: Exclusive Interview with Dr. Wade Weigel
Q5. What are the key points of the UK AAGBI 2021 guidelines on management of neuromuscular blockade?

Q5. What are the key points of the UK AAGBI 2021 guidelines on management of neuromuscular blockade?
Q6. What is the most useful site for neuromuscular monitoring and what are the alternatives options?

Q6. What is the most useful site for neuromuscular monitoring and what are the alternatives options?
Q10. What are the advantages of using EMG monitors?

Q10. What are the advantages of using EMG monitors?
Q11. What are the highlights of Europe ESAIC 2023 guidelines on management of neuromuscular blockade

Q11. What are the highlights of Europe ESAIC 2023 guidelines on management of neuromuscular blockade
Q14. What are the key points of the US ASA 2023 guidelines on management of neuromuscular blockade?

Q14. What are the key points of the US ASA 2023 guidelines on management of neuromuscular blockade?
Q17. What are the latest usage data and practices for NMT monitoring in Europe?

Q17. What are the latest usage data and practices for NMT monitoring in Europe?
Q18. Is a TOF Ratio above 100% on an AMG system an artefact?

Q18. Is a TOF Ratio above 100% on an AMG system an artefact?
Q19. How do we effectively implement change/adoption of routine neuromuscular blockade monitoring?

Q19. How do we effectively implement change/adoption of routine neuromuscular blockade monitoring?
Dr Grant Rodney and Objective Neuromuscular Block monitoring

Dr Grant Rodney and Objective Neuromuscular Block monitoring
Q16. Sugammadex vs Neostigmine What are the clinical outcome differences and associate risks

Q16. Sugammadex vs Neostigmine What are the clinical outcome differences and associate risks
Q20. Are we moving in the right direction to eliminate RNB by 2025?

Q20. Are we moving in the right direction to eliminate RNB by 2025?
Q26. Can we avoid NMBA’s in rapid sequence intubationRSI

Q26. Can we avoid NMBA’s in rapid sequence intubationRSI
Q4. What are the key points of the Belgium SARB 2019 guidelines on management of neuromuscular block

Q4. What are the key points of the Belgium SARB 2019 guidelines on management of neuromuscular block
Q7. What are the risks of facial nerve monitoring?

Q7. What are the risks of facial nerve monitoring?
Q12. When should Neostigmine be used as a reversal agent according to the ESAIC guidelines?

Q12. When should Neostigmine be used as a reversal agent according to the ESAIC guidelines?
Q27. Can we use Remifentanil instead of Neuromuscular blockers for intubation?

Q27. Can we use Remifentanil instead of Neuromuscular blockers for intubation?
Q28. What are the unique risks for the paediatric population in management of neuromuscular block?

Q28. What are the unique risks for the paediatric population in management of neuromuscular block?
Q21. What are the most common pitfalls in neuromuscular blockade management?

Q21. What are the most common pitfalls in neuromuscular blockade management?
Q15. Do we need to monitor when using Sugammadex?

Q15. Do we need to monitor when using Sugammadex?
Q25. What are the risks of unmonitored antagonization of neuromuscular block?

Q25. What are the risks of unmonitored antagonization of neuromuscular block?
Q3. How can we convince our hospital to invest in Objective NMT Monitoring?

Q3. How can we convince our hospital to invest in Objective NMT Monitoring?
Q2. What is the incidence rate of residual block when using succinylcholine and how important is it?

Q2. What is the incidence rate of residual block when using succinylcholine and how important is it?
Q24. How dependable is the time since my last dose of relaxant to determine the time of extubation?

Q24. How dependable is the time since my last dose of relaxant to determine the time of extubation?
Q23. My patient is breathing and moving Are they ready for extubation?

Q23. My patient is breathing and moving Are they ready for extubation?
Q9. Which muscles are more resistant to neuromuscular blocking agents?

Q9. Which muscles are more resistant to neuromuscular blocking agents?